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CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats) are the segments of prokary-
otic DNA containing short repeats in its nucleotide sequence. Today we know that this is a bacterial 
protection system against viral DNA. The molecular components of CRISPR/Cas9 system have been 
used for a gene editing in eukaryotes since 2013. But as any other method it also has the limitations 
and drawbacks. Here we are going to review the history of CRISPR biology and to discuss the possi-
bilities that this new technology provides to researchers as well as the prospects for its use in the 
medical research and treatment.
K e y w o r d s: CRISPR/Cas9, genome targeting, genome editing, personalized therapy, chromosomal 
translocations, DNA repair.
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History
The specifi c sequences in bacterial genomes, called 
CRISPR, were discovered in 1987. They consist of 
repeats, alternating by unique sequences or «spac-
ers» [1] (Fig. 1, A). Its function has been unsolved 
until 2005 when it was found that these «spacers» 
have a sequence equal to a viral DNA. It was also 
observed that there are the CRISPR-associated 
genes and these genes encode nucleases. After-
wards it was supposed that the bacteria use these 
nucleases to cleave a foreign DNA wherein the 
spacer sequence is used as an example of which ex-
actly DNA sequence is necessary to be cut [2, 3]. 
This hypothesis was experimentally proven in 2007 
[4]. A detailed mechanism of the complex matura-
tion and directed cleavage of DNA was fi nally stud-
ied in 2011 [5] (Fig. 1, B). It was found that the 
Cas9 enzyme formed a ternary complex with crRNA 
and tracrRNA encoded in the cluster. This complex 
unwinds DNA and introduce a double-stranded 
break in DNA if crRNA binds complementary to 
one of the DNA chains (Fig. 2, A). A year later it 
was shown that crRNA can be joint to tracrRNA 
and that this «single guide» RNA (sgRNA) together 
with the Cas9 enzyme might be used to modify the 
genome of eukaryotes [6] (Fig. 2, B)..This idea was 
realized in 2013 and since then thousands of papers 
where such technology was applied have been pub-
lished [7–9].
The approaches to targeted DNA breakage based 
on the usage of zinc fi nger nucleases (ZFNs) and 
TAL effector nucleases (TALENs) were developed 
much earlier in 2003 and 2009 respectively. Both 
methods are based on the DNA recognition by the 
specifi c proteins designed individually for each par-
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ticular sequence [10, 11]. Compared to the these 
technologies the CRISPR/Cas9 system has proved to 
be much more simple, available, affordable and three 
to four times more effi cient [12].
The basic principle
of CRISPR/Cas9 technology
At the heart of all the methods that use the CRISPR/
Cas9 system lies the possibility to introduce a break 
in DNA in an exactly desired locus. It’s enough to 
deliver the Cas9 gene (or its mRNA) together with 
sgRNA into the cell, wherein sgRNA at its 5’-end 
should have 20 nucleotide sequence complimentary 
to a target DNA fragment. There is also easy way to 
introduce the multiple breaks at the same time – just 
to use several different sgRNAs [13].
Application of CRISPR/Cas9 technology
The fi rst example of application of the CRISPR/
Cas9 technology is the modeling of tumor-associat-
ed chromosomal translocations: CRISPR/Cas9 in-
duces the double-stranded DNA breaks (DSBs) in 
the precise loci which are known to participate in the 
oncogenic rearrangements. Typically, DSBs used to 
be repaired by the mechanism of non-homologous 
end joining (NHEJ). This error prone mechanism fre-
quently leads to joining the DNA ends belonging to 
different chromosomes [14]. The cellular models of 
certain types of cancer might be obtained using this 
method. Inducing the human specifi c types of cancer 
in laboratory animals is also possible. So, the mu rine 
model of non-small-cell lung cancer (NSCLC) was 
developed. Using lentiviral delivery the Cas9 gene 
and sgRNA were brought into lung cells in order to 
induce a cleavage of the murine endogenous Eml4 
and Alk loci and to generate the Eml4-Alk fused gene 
found recurrently in NSCLCs. The result was the de-
velopment of the disease in the treated mice [15]. To 
date the murine in vivo models of human leukemia 
(namely, AML) have also been developed [16, 17]. 
These and other similar murine models can be uti-
lized to study the carcinogenesis and to test new 
treatment approaches.
The next purpose which might be successfully 
achieved by application of the CRISPR/Cas9 technol-
ogy is knocking genes out. The DSB formation often 
leads to the deletion or insertion of several nucleotides 
in an initial sequence even in case of effi cient DSB 
repair [18]. Thus, introducing a break into a particular 
gene one may cause its knockout. So the Cas9-ex-
pressing cell line treated with various sgRNA can be 
used for searching for the genes responsible for a spe-
cifi c disease. A few years earlier each gene knockout 
was a complicated time-consuming procedure, but in 
case of CRISPR/Cas9 it requires only to treat the 
Cas9-expressing cells with a specifi c sgRNA [19].
In addition, one may insert the desired DNA frag-
ment into the specifi c broken DNA site. There are 
Fig. 2. A – Targeted cleavage of DNA by a ternary complex of 
Cas9 with crRNA and tracrRNA. B – Targeted cleavage of DNA 
by a complex of Cas9 with «single guide» RNA (sgRNA)
Fig. 1. A – The overall structure of the CRISPR loci. B – Mech-
anism of CRISPR/Cas9 complex maturation
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two major mechanisms of DSB repair: homology-
directed repair (HDR) and non-homologous end 
joining (NHEJ). HDR requires a fragment of DNA 
homologous to the damaged one as a template. Oth-
erwise, in the absence of such a fragment, NHEJ 
takes place. It is possible to achieve insertion of a 
desired DNA fragment in both cases. If a DNA frag-
ment with homology arms surrounding a desired 
gene is available, it will be inserted via HDR. In case 
of the NHEJ repair it is suffi cient to deliver a linear 
DNA fragment with the ends protected from the ac-
tion of cellular exonucleases. There is a chance that 
this fragment will be joined to the ends of the break.
So, the CRISPR/Cas9 technology makes possible 
the insertion of the desired DNA fragment into the ge-
nome. It is widely used in scientifi c research and offers 
great opportunities for the treatment of hereditary dis-
eases and viral infections. For example, this technology 
allows generation of the stable cell lines with the de-
sired inserts in the genome. The CRISPR/Cas9 gene 
knocking occurs with a much higher effi ciency than the 
random integration of a plasmid into the genome and 
solely at the particular pre-selected site in almost 100 % 
of cases. Until recently the generation of a stable cell 
line usually took at least few months, with the CRISPR/
Cas9 technology – up to one month [20].
Moreover, until recently, the gene therapy implied 
the insertion of the desired gene into the random place 
in the genome. In its turn, the CRISPR/Cas9 system 
allows changes in a certain place, where one may not 
only insert the gene but also remove or replace the 
certain DNA fragments. Several in vivo studies in 
mice have shown the possibility of gene therapy by 
means of the CRISPR/Cas9 application. A deletion of 
1 bp in the CRYGC gene is known to cause the cata-
ract in mice. After injection of the Cas9 mRNA, 
sgRNA and the DNA fragment containing a wild-type 
allele into the mouse embryos with this mutation the 
mousekins were born healthy [21]. In a recent work 
the researchers have successfully applied the CRISPR/
Cas9 system in order to reduce the level of cholesterol 
in the blood of mice by turning off the PCSK9 gene in 
the liver cells. They used adenovirus particles to de-
liver the Cas9 gene and sgRNA into hepatocytes. As a 
result more than 50 % of hepatocytes were «edited» 
and it resulted in a decrease in the cholesterol level to 
a value that is typical for the PCSK9 knockout mice 
[22]. Striking results were achieved with CRISPR/
Cas9 in the prevention of Duchene’s muscular dystro-
phy (DMD) in mice by correcting the dmd dystrophin 
gene. A copy of the normal dmd gene was integrated 
in the zygotes via the CRISPR/Cas9 system. The born 
animals were mosaic in the dmd gene but nonetheless 
even a partial gene editing has prevented the disease 
development [23].
The ability to deliver the CRISPR/Cas9 system 
elements into the brain cells has been also recently 
demonstrated. Because of the packaging size limita-
tion of the adeno-associated viral (AAV) vectors, the 
dual-vector system was designed composed of two se-
parate vectors that package the SpCas9 (AAV-SpCas9) 
and sgRNA (AAV-SpGuide) expression cassettes. 
However, the co-transfection effi ciency was shown 
to be rather high [19].
Taken together, these in vivo studies on animals 
prove the excellent prospects for the genome editing 
via application of the CRISPR/Cas9 technology.
On the other hand, many studies ex vivo show the 
ability to edit DNA in human cells. The particular 
mutations in the CCR5 gene which occur in some 
people are known to make it resistant to HIV. A re-
cent study has established that the CRISPR/Cas9-
based editing of CCR5 in the induced pluripotent 
stem cells (iPSCs) may lead to the HIV-1 resistance 
of descendant lymphocytes [12].
The possibility to treat the latent virus infection 
has also been recently demonstrated: the patient-de-
rived cells from a Burkitt’s lymphoma with latent 
Epstein–Barr virus infection showed a proliferation 
arrest and a concomitant decrease in viral load after 
targeting the viral genome by the CRISPR/Cas9 sys-
tem elements [24]. Finally, the healthy gene copy 
was introduced in cells of the patients with cystic fi -
brosis via CRISPR/Cas9. As a result the cells dem-
onstrated a healthy phenotype [25].
Taken together with the fact demonstrating that 
the «in vitro corrected» organs might be successfully 
transplanted back into the body in mice [26], the 
above experiments give us a hope for the successful 
application of this experience in the treatment of pa-
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tients. This considerably strengthens the position of 
gene therapy among the advanced treatments of the 
genetic and viral diseases in humans.
An especial theme is the editing of the human em-
bryo genome. Such possibility opens up broad pros-
pects for the prenatal correction of the «broken» 
genes. The researchers from Sun Yat-sen University, 
China, have already tested this potential. They used 
triplonuclear zygotes (for ethical reasons) and re-
placed the HBB gene using the CRISPR/Cas9 tech-
nique. As a result it was shown that: 1) the effective-
ness of the replacement of a normal gene copy by 
means of HDR in these cells was relatively low; 2) the 
edited embryos were mosaic; 3) the mutations in the 
genome located in not-planned loci was identifi ed (so-
called «off-target» mutations); 4) another high ly ho-
mologous gene (HBD) could serve as a donor tem-
plate for HDR. However, despite the diffi culties this 
study shows the fundamental possibility of the ge-
nome editing in human embryos [27].
Drawbacks of CRISPR/Cas9 technology
The common problem of all genome editing meth-
ods is so called «off-target» effects – when a nucle-
ase cleaves DNA not in the place where it was in-
tended. It may impair the function of any incidental 
gene or may lead to integration of the desired gene in 
the wrong place and genome surrounding. In case of 
human embryos such a risk is absolutely unaccepta-
ble. In the abovementioned work with the human 
embryos several off-target mutations have been fo-
und and documented, but later the authors noticed 
that three out of four of them were polymorphisms 
already presented in the germline and were not as-
sociated with the CRISPR/Cas9 action. The special 
studies show that the level of off-target mutations in 
case of the CRISPR/Cas9 application is in fact ex-
tremely low [28]. Today, several methods for meas-
uring the off-target editing have been developed. The 
fi rst method is based on the fl uorescent in situ hy-
bridization (FISH): one fl uorescent probe anneals to 
the insertion fragment and another fl uorescent probe 
detects the insertion site. Normally these two probes 
have to be colocalized otherwise it is the erroneous 
insertion [29]. Other method (GUIDE-seq) is based 
on the addition of short DNA fragments which would 
be integrated at the breaks. These fragments of DNA 
are then used as anchors when surrounding DNA is 
amplifi ed by PCR and sequenced. So one we can see 
all sites of insertion of these fragments and count 
off-target mutations [30]. These eva luation methods 
have shown that not all of the off-target sites might 
be predicted by special computer software and that 
the different sgRNA provides a different number of 
these effects.
The various methods to improve the accuracy and 
effi ciency of insertion were proposed. For example, 
in order to obtain a higher specifi city a «double nick-
ing» method might be used [31]. It consists in spe-
cial modifi cation of Cas9 resulting in an ability of 
the enzyme to introduce break in only one DNA 
strand («nick»). Thus, for the formation of a double-
stranded break two such nickases should work vis-a-
vis. Furthermore, each of the enzymes has to bind its 
own sgRNA which should recognize its own (mutu-
ally complementary) DNA sequence. Thus, the prob-
ability of double-stranded breakage in the off-target 
sites reduces dramatically.
In order to increase the effi ciency of the insertion 
in the genome the HDR mechanism should prevail. 
To achieve this goal the NHEJ-inhibiting agents 
might be used. In particular DNA ligase IV which 
plays an important role in NHEJ might be turned off 
by using the Scr7 agent. This may increase the effi -
cacy of DNA integration up to 19 times [32].
The selection of sgRNA sequences should be per-
formed in such a way to reduce the probability of the 
off-target effects. The special algorithms have been 
developed for this purpose (CRISPR Design Tool: 
http://tools.genome-engineering.org). If there is need 
for especial accuracy it is necessary to check a num-
ber of the off-target sites by applying the GUIDE-
seq technique.
Finally, the integration of new genes requires a 
special attention when selecting the integration site. 
Such target should be a locus where the inserted DNA 
fragment would be «protected» against the epige-
netic effects, would work in a predictable manner 
and would not cause negative effects on a cell, for 
example, induce carcinogenesis. Such loci are called 
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«genomic safe harbors» (GSHs). They should be lo-
cated far from other genes especially protooncogenes 
and at the same time should be outside the transcrip-
tion units and the ultra-conserved DNA regions. The 
sites suitable as GSHs might be identifi ed by the bio-
informatics methods but also require experimental 
confi rmation [33].
Conclusion
So far we can say with confi dence that the CRISPR/
Cas9-based technologies have revolutionized the bio-
medical science and are spreading at a remarkable 
speed by virtue of their simplicity and effi ciency. 
The CRISPR/Cas9 application dramatically facili-
tates the manipulation with DNA in terms of provid-
ing the targeted genome editing, foremost deletions 
or gene replacement. Despite some drawbacks this 
technology has a wide perspective in the fi elds of 
basic research, biotechnology, translational and per-
sonalized medicine.
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CRISPR/Cas9 технологія
для цільового редагування геному
Н. А. Ломов, В. В. Борунова, М. А. Рубцов
CRISPRs (Clustered Regularly Interspaced Short Palindromic 
Repeats) – послідовності в геномі прокариот, які складають-
ся з коротких повторів, що перемежовуються унікальними 
послідовностями. Це система бактеріальної захисту від ві-
русної ДНК. Молекулярні компоненти даної системи з 2013 
року використовуються як інструмент редагування еукаріо-
тічесого геному, хоча дана технологія і має деякі обмежен-
ня і недоліки. У даному огляді ми торкнемося історію за-
стосування системи CRISPR / Cas9 і обговоримо можливос-
ті, які дана технологія надає для дослідження і лікування 
різних захворювань. 
Ключевые  слова: CRISPR/Cas9, тагретінг генома, 
редагування геному, персоналізована терапія, хромосомні 
транслокації, репарація ДНК.
CRISPR/Cas9 технология
для целевого редактирования генома
Н. А. Ломов, В. В. Борунова, М. А. Рубцов
CRISPRs (Clustered Regularly Interspaced Short Palindromic 
Repeats) – последовательности в геноме прокариот, которые 
состоят из коротких повторов, перемежающихся уникаль-
ными последовательностями. Это система бактериальной 
защиты от вирусной ДНК. Молекулярные компоненты дан-
ной системы с 2013 года используются как инструмент ре-
дактирования эукариотического генома, хотя данная техно-
логия и имеет некоторые ограничения и недостатки. В дан-
ном обзоре мы затронем историю применения системы 
CRISPR/Cas9 и обсудим возможности, которые данная тех-
нология предоставляет для исследования и лечения различ-
ных заболеваний.
Ключевые  слова: CRISPR/Cas9, таргетинг генома, 
редактирование генома, персонализированая терапия, 
хромосоные транслокации, репарация ДНК.
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